Question · asked by 1 review
Levetiracetam vs placebo: Leaving the study early
- Population
- patients with antipsychotic‐induced tardive dyskinesia
- Intervention
- Levetiracetam
- Comparison
- placebo
- Outcome
- Leaving the study early
It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty).
What each review found
Current versions only| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
ANTIEPILEPTIC ‐ LEVETIRACETAM vs PLACEBO Acceptability of treatment (measured by participants leaving the study early) · female and male 47‐54 years old (mean) patients with various psychiatric conditions and antipsychotic‐induced tardive… It is very uncertain whether ANTIEPILEPTIC ‐ LEVETIRACETAM changes acceptability of treatment (measured by participants leaving the… compared with PLACEBO (very low certainty). Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia (2018) · Cochrane Headline outcomes only | RR 1.01 [0.46, 2.22] | 2 studies · 119 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Miscellaneous treatments for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.